TI
ENTA icon

Trexquant Investment’s Enanta Pharmaceuticals ENTA Stock Holding History

Trexquant Investment’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
69,613
+13,446
+24% +$181K 0.01% 1459
2026
Q1 		$709K Buy
+56,167
New +$753K 0.01% 1346
2025
Q4 		– Sell
-127,363
Closed -$1.52M – 1670
2025
Q3 		$1.52M Sell
127,363
-137,595
-52% -$1.1M 0.02% 1011
2025
Q2 		$2M Sell
264,958
-25,101
-9% -$151K 0.02% 883
2025
Q1 		$1.6M Buy
290,059
+154,105
+113% +$952K 0.02% 939
2024
Q4 		$782K Buy
135,954
+67,040
+97% +$643K 0.01% 1177
2024
Q3 		$714K Sell
68,914
-10,009
-13% -$131K 0.01% 1160
2024
Q2 		$1.02M Sell
78,923
-16,716
-17% -$226K 0.02% 994
2024
Q1 		$1.67M Sell
95,639
-22,973
-19% -$304K 0.03% 714
2023
Q4 		$1.12M Sell
118,612
-13,949
-11% -$130K 0.03% 785
2023
Q3 		$1.48M Buy
+132,561
New +$2.14M 0.04% 597
2022
Q4 		– Sell
-4,882
Closed -$253K – 1460
2022
Q3 		$253K Sell
4,882
-1,370
-22% -$80K 0.01% 1099
2022
Q2 		$296K Buy
+6,252
New +$339K 0.01% 1126
2021
Q3 		– Sell
-7,958
Closed -$350K – 1228
2021
Q2 		$350K Buy
+7,958
New +$390K 0.03% 636
2021
Q1 		– Sell
-7,124
Closed -$300K – 1200
2020
Q4 		$300K Sell
7,124
-8,514
-54% -$375K 0.03% 689
2020
Q3 		$716K Buy
15,638
+7,802
+100% +$378K 0.05% 536
2020
Q2 		$393K Buy
+7,836
New +$406K 0.03% 767
2019
Q3 		– Sell
-3,824
Closed -$323K – 925
2019
Q2 		$323K Sell
3,824
-11,180
-75% -$1.01M 0.03% 580
2019
Q1 		$1.43M Buy
+15,004
New +$1.35M 0.1% 287
2018
Q3 		– Sell
-5,266
Closed -$610K – 1005
2018
Q2 		$610K Buy
+5,266
New +$525K 0.04% 486
2018
Q1 		– Sell
-8,620
Closed -$506K – 1154
2017
Q4 		$506K Buy
+8,620
New +$432K 0.06% 509

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Trexquant Investment's ENTA Position: Q2 2026 in Review

Trexquant Investment increased its Enanta Pharmaceuticals (ENTA) stake by 24% in Q2 2026, buying an estimated $181K and bringing the position to 69,613 shares worth $1.01M. The position accounts for 0.01% of the portfolio, ranked #1459.

Trexquant Investment first reported a position in ENTA in Q4 2017 and has held it in 21 quarters since. The position peaked at $2M in Q2 2025. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Trexquant Investment held 69,613 shares of Enanta Pharmaceuticals worth $1.01M as of Q2 2026.
  • Trexquant Investment bought 13,446 Enanta Pharmaceuticals shares in Q2 2026, an estimated $181K.
  • Enanta Pharmaceuticals made up 0.01% of Trexquant Investment's portfolio in Q2 2026, its #1459 holding.
  • Trexquant Investment first reported a position in Enanta Pharmaceuticals in Q4 2017 and has held it in 21 quarters since.
  • Trexquant Investment's Enanta Pharmaceuticals position peaked at $2M in Q2 2025.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.